Arrow-right Camera

The Spokesman-Review Newspaper The Spokesman-Review

Friday, August 23, 2019  Spokane, Washington  Est. May 19, 1883
Clear Night 58° Clear
News >  Health

FDA approves 9 generic versions of nerve pain drug Lyrica

The U.S. Food and Drug Administration building can be seen behind FDA logos at a bus stop on the agency’s campus in Silver Spring, Md. (Jacquelyn Martin / AP)
The U.S. Food and Drug Administration building can be seen behind FDA logos at a bus stop on the agency’s campus in Silver Spring, Md. (Jacquelyn Martin / AP)
By Linda A. Johnson Associated Press

TRENTON, N.J. – The U.S. Food and Drug Administration has approved the first generic copies of a popular, pricey pill for nerve pain.

The agency on Monday said it approved nine generic versions of Pfizer Inc.’s Lyrica. It is also used for seizures and fibromyalgia, a condition that causes chronic, widespread pain.

Lyrica, approved in 2004, is Pfizer’s second bestseller, with sales last year of $4.6 billion. The heavily advertised drug costs about $460 to $720 per month without insurance, depending on the pharmacy. Prices can vary widely.

Prices for generic versions range from about $140 to $370 per month, according to the drug price comparison site GoodRx.

Common side effects include dizziness, blurred vision and sleepiness. Serious side effects include allergic reactions and life-threatening breathing problems.

Subscribe to the Morning Review newsletter

Get the day’s top headlines delivered to your inbox every morning by subscribing to our newsletter.

You have been successfully subscribed!
There was a problem subscribing you to the newsletter. Double check your email and try again, or email webteam@spokesman.com